Lemaitre Vascular Inc LMAT
Lemaitre Vascular Inc (Nasdaq: LMAT) is a medical device company. Its next catalyst on record is Allograft tissue processing transfer: Transfer from Fox River Grove facility to Burlington substantially complete (December 2026).
Upcoming catalysts
- December 2026Allograft tissue processing transfer — Transfer from Fox River Grove facility to Burlington substantially complete
In February 2026, we announced the transition of our allograft tissue processing from our Fox River Grove facility to Burlington. This transition is expected to be substantially complete by the end of 2026.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.